Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1998 Jul;65(1):60–64. doi: 10.1136/jnnp.65.1.60

Dopamine transporter imaging with [123I]-β-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease

B Jeon 1, J Kim 1, J Jeong 1, K Kim 1, Y Chang 1, D Lee 1, M Lee 1
PMCID: PMC2170169  PMID: 9667562

Abstract

OBJECTIVES—The most common neurological manifestations in Wilson's disease are parkinsonism and dystonia. These are assumed to be due to striatal injury, which has been repeatedly demonstrated by pathology and CT or MRI. The substantia nigra has not been shown to be damaged in pathological studies. However, there have been clinical and imaging studies suggesting presynaptic nigrostriatal injury. (1r)-2β-carbomethoxy-3β-(4-iodophenyl)tropane (β-CIT) is a specific ligand that binds to the dopamine transporter (DAT), and can examine the integrity of dopaminergic nerve terminals. Evidence for presynaptic nigrostriatal dopaminergic damage in Wilson's disease was searched for using [123I]-β-CIT SPECT.
METHODS—Six patients with Wilson's disease were studied, together with 15 healthy normal controls, and six patients with Parkinson's disease. After injection of [123I]-β-CIT, SPECT studies were done at 18 hours. Specific striatal/occipital binding ratio (S/O ratio) was calculated as (striatal binding−occipital binding)/occipital binding.
RESULTS—The specific S/O ratios were 6.22 (1.32) (mean (SD)) in normal volunteers, 3.78 (0.65) in Parkinson's disease, and 3.60 (0.49) in Wilson's disease.
CONCLUSION—There was severe loss of the DAT in the striatum suggesting significant damage in presynaptic nigrostriatal dopaminergic nerve terminals. Therefore, a presynaptic lesion may contribute to neurological manifestations in Wilson's disease.



Full Text

The Full Text of this article is available as a PDF (137.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aisen A. M., Martel W., Gabrielsen T. O., Glazer G. M., Brewer G., Young A. B., Hill G. Wilson disease of the brain: MR imaging. Radiology. 1985 Oct;157(1):137–141. doi: 10.1148/radiology.157.1.4034959. [DOI] [PubMed] [Google Scholar]
  2. Barbeau A., Friesen H. Treatment of Wilson's disease with L-dopa after failure with penicillamine. Lancet. 1970 May 30;1(7657):1180–1181. doi: 10.1016/s0140-6736(70)91259-6. [DOI] [PubMed] [Google Scholar]
  3. Burke R. E., Kent J., Kenyon N., Karanas A. Unilateral hypoxic-ischemic injury in neonatal rat results in a persistent increase in the density of striatal tyrosine hydroxylase immunoperoxidase staining. Brain Res Dev Brain Res. 1991 Feb 22;58(2):171–179. doi: 10.1016/0165-3806(91)90003-2. [DOI] [PubMed] [Google Scholar]
  4. Burke R. E., Reches A. Preserved striatal tyrosine hydroxylase activity, assessed in vivo, following neonatal hypoxia-ischemia. Brain Res Dev Brain Res. 1991 Aug 19;61(2):277–280. doi: 10.1016/0165-3806(91)90143-7. [DOI] [PubMed] [Google Scholar]
  5. Kendall B. E., Pollock S. S., Bass N. M., Valentine A. R. Wilson's disease. Clinical correction with cranial computed tomography. Neuroradiology. 1981;22(1):1–5. doi: 10.1007/BF00344602. [DOI] [PubMed] [Google Scholar]
  6. Kilbourn M. R., Sherman P. S., Pisani T. Repeated reserpine administration reduces in vivo [18F]GBR 13119 binding to the dopamine uptake site. Eur J Pharmacol. 1992 May 27;216(1):109–112. doi: 10.1016/0014-2999(92)90216-q. [DOI] [PubMed] [Google Scholar]
  7. Laruelle M., Baldwin R. M., Malison R. T., Zea-Ponce Y., Zoghbi S. S., al-Tikriti M. S., Sybirska E. H., Zimmermann R. C., Wisniewski G., Neumeyer J. L. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse. 1993 Apr;13(4):295–309. doi: 10.1002/syn.890130402. [DOI] [PubMed] [Google Scholar]
  8. Marek K. L., Seibyl J. P., Zoghbi S. S., Zea-Ponce Y., Baldwin R. M., Fussell B., Charney D. S., van Dyck C., Hoffer P. B., Innis R. P. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology. 1996 Jan;46(1):231–237. doi: 10.1212/wnl.46.1.231. [DOI] [PubMed] [Google Scholar]
  9. Morgan J. P., Preziosi T. J., Bianchine J. R. Ineffectiveness of L-dopa as supplement to penicillamine in a case of Wilson's disease. Lancet. 1970 Sep 26;2(7674):659–659. doi: 10.1016/s0140-6736(70)91422-4. [DOI] [PubMed] [Google Scholar]
  10. Nyberg P., Gottfries C. G., Holmgren G., Persson S., Roos B. E., Winblad B. Advanced catecholaminergic disturbances in the brain in a case of Wilson's disease. Acta Neurol Scand. 1982 Jan;65(1):71–75. doi: 10.1111/j.1600-0404.1982.tb03063.x. [DOI] [PubMed] [Google Scholar]
  11. Oertel W. H., Tatsch K., Schwarz J., Kraft E., Trenkwalder C., Scherer J., Weinzierl M., Vogl T., Kirsch C. M. Decrease of D2 receptors indicated by 123I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson's disease. Ann Neurol. 1992 Dec;32(6):743–748. doi: 10.1002/ana.410320607. [DOI] [PubMed] [Google Scholar]
  12. Perrone-Capano C., Tino A., Amadoro G., Pernas-Alonso R., di Porzio U. Dopamine transporter gene expression in rat mesencephalic dopaminergic neurons is increased by direct interaction with target striatal cells in vitro. Brain Res Mol Brain Res. 1996 Jul;39(1-2):160–166. doi: 10.1016/0169-328x(96)00022-8. [DOI] [PubMed] [Google Scholar]
  13. Prayer L., Wimberger D., Kramer J., Grimm G., Oder W., Imhof H. Cranial MRI in Wilson's disease. Neuroradiology. 1990;32(3):211–214. doi: 10.1007/BF00589114. [DOI] [PubMed] [Google Scholar]
  14. Przedborski S., Kostic V., Jackson-Lewis V., Cadet J. L., Burke R. E. Effect of unilateral perinatal hypoxic-ischemic brain injury in the rat on dopamine D1 and D2 receptors and uptake sites: a quantitative autoradiographic study. J Neurochem. 1991 Dec;57(6):1951–1961. doi: 10.1111/j.1471-4159.1991.tb06409.x. [DOI] [PubMed] [Google Scholar]
  15. Roh J. K., Lee T. G., Wie B. A., Lee S. B., Park S. H., Chang K. H. Initial and follow-up brain MRI findings and correlation with the clinical course in Wilson's disease. Neurology. 1994 Jun;44(6):1064–1068. doi: 10.1212/wnl.44.6.1064. [DOI] [PubMed] [Google Scholar]
  16. Schwarcz R., Hökfelt T., Fuxe K., Jonsson G., Goldstein M., Terenius L. Ibotenic acid-induced neuronal degeneration: a morphological and neurochemical study. Exp Brain Res. 1979 Oct;37(2):199–216. doi: 10.1007/BF00237708. [DOI] [PubMed] [Google Scholar]
  17. Schwarcz R., Whetsell W. O., Jr, Mangano R. M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science. 1983 Jan 21;219(4582):316–318. doi: 10.1126/science.6849138. [DOI] [PubMed] [Google Scholar]
  18. Snow B. J., Bhatt M., Martin W. R., Li D., Calne D. B. The nigrostriatal dopaminergic pathway in Wilson's disease studied with positron emission tomography. J Neurol Neurosurg Psychiatry. 1991 Jan;54(1):12–17. doi: 10.1136/jnnp.54.1.12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Uhl G. R. Neurotransmitter transporters (plus): a promising new gene family. Trends Neurosci. 1992 Jul;15(7):265–268. doi: 10.1016/0166-2236(92)90068-j. [DOI] [PubMed] [Google Scholar]
  20. Vander Borght T., Kilbourn M., Desmond T., Kuhl D., Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol. 1995 Dec 29;294(2-3):577–583. doi: 10.1016/0014-2999(95)00594-3. [DOI] [PubMed] [Google Scholar]
  21. Volkow N. D., Ding Y. S., Fowler J. S., Wang G. J., Logan J., Gatley S. J., Hitzemann R., Smith G., Fields S. D., Gur R. Dopamine transporters decrease with age. J Nucl Med. 1996 Apr;37(4):554–559. [PubMed] [Google Scholar]
  22. Westermark K., Tedroff J., Thuomas K. A., Hartvig P., Långström B., Andersson Y., Hörnfeldt K., Aquilonius S. M. Neurological Wilson's disease studied with magnetic resonance imaging and with positron emission tomography using dopaminergic markers. Mov Disord. 1995 Sep;10(5):596–603. doi: 10.1002/mds.870100511. [DOI] [PubMed] [Google Scholar]
  23. Williams F. J., Walshe J. M. Wilson's disease. An analysis of the cranial computerized tomographic appearances found in 60 patients and the changes in response to treatment with chelating agents. Brain. 1981 Dec;104(Pt 4):735–752. doi: 10.1093/brain/104.4.735. [DOI] [PubMed] [Google Scholar]
  24. Wilson J. M., Nobrega J. N., Carroll M. E., Niznik H. B., Shannak K., Lac S. T., Pristupa Z. B., Dixon L. M., Kish S. J. Heterogeneous subregional binding patterns of 3H-WIN 35,428 and 3H-GBR 12,935 are differentially regulated by chronic cocaine self-administration. J Neurosci. 1994 May;14(5 Pt 2):2966–2979. doi: 10.1523/JNEUROSCI.14-05-02966.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Yuh W. T., Flickinger F. W. Unusual MR findings in CNS Wilson disease. AJR Am J Roentgenol. 1988 Oct;151(4):834–834. doi: 10.2214/ajr.151.4.834-a. [DOI] [PubMed] [Google Scholar]
  26. Zea-Ponce Y., Baldwin R. M., Laruelle M., Wang S., Neumeyer J. L., Innis R. B. Simplified multidose preparation of iodine-123-beta-CIT: a marker for dopamine transporters. J Nucl Med. 1995 Mar;36(3):525–529. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES